RNAi Agents Targeting APOC3 for Hypertriglyceridemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective agents to inhibit the function of apolipoprotein C-III, which is associated with hypertriglyceridemia and other metabolic disorders, highlighting a need for novel approaches to manage these conditions.
Innovation Solution
Development of RNAi agents specifically targeting apolipoprotein C-III (APOC3) to inhibit its expression and activity, utilizing various sequence formats and modifications for enhanced efficacy and stability, including 18-mer and 19-mer formats with terminal dinucleotides and caps, to reduce APOC3 levels in subjects with related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNAi agents are developed to inhibit APOC3 expression, then therapeutic efficacy for hypertriglyceridemia is improved, but agent stability and delivery challenges increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of RNAi agents through various nucleotide modifications (2'-O-methyl, phosphorothioate linkages, morpholino structures) and optimizing sequence parameters (18-mer and 19-mer formats with specific terminal dinucleotides). These parameter changes enhance the stability of RNAi agents against nucleases while maintaining their ability to inhibit APOC3 expression, thereby resolving the contradiction between therapeutic efficacy and agent stability.
2Reliability
If RNAi agents with modified sequences are used to enhance efficacy, then inhibition of APOC3 is improved, but complexity of the agent increases
Solution Approach 1:
The patent applies local quality by introducing specific modifications at particular positions within the RNAi agent sequence rather than uniformly modifying the entire structure. For example, terminal dinucleotides are specifically modified with certain sequences, and phosphorothioate linkages are placed at specific positions. This localized approach enhances inhibition efficacy while minimizing overall structural complexity, allowing the agent to maintain simplicity where possible while achieving enhanced function at critical positions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi agents effectively decrease APOC3 expression and activity, providing a therapeutic option for treating hypertriglyceridemia and other metabolic disorders by selectively targeting and reducing apolipoprotein C-III levels, thereby addressing the underlying cause of these conditions.
Implementation Method 1
RNAi agents specifically targeting apolipoprotein C-III (APOC3) to inhibit its expression and activity
Data Source
AI summary
The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.